15

20

1. A compound of Formula (I):

or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents:

a substituted or unsubstituted, (preferably aromatic), carbocyclic or heterocyclic group, said carbocyclic or heterocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, any heteroatoms being selected from N, O and S, any substituents on the Ar group being independently selected from the group consisting of:

(a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ lower alkyl (in particular CH₃), (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁶ are the same or different and each represents H or lower C₁₋₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

CI, Br, F, OMe, NO₂ and CF₃,

and (I) -OCOR¹¹, wherein R¹¹ represents a saturated or unsaturated lower C_{1.6} straight or branched hydrocarbyl group or a phenyl group;

R represents

OH, OR¹⁰ or OCOR¹¹, wherein R¹⁰ and R¹¹ are as defined above; and R¹ represents H or a lower C₁₋₆ straight or branched hydrocarbyl group which may be

5

unsubstituted or substituted by 1, 2 or 3 substituents selected from CI, Br, F, OMe, NO₂ and CF₃.

- 2. A compound according to Claim 1 wherein Ar represents a substituted or unsubstituted (preferably aromatic), heterocyclic group said heterocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, the heteroatoms being selected from N, O and S, and any substituents on the Ar group being independently selected from the group consisting of:
 - (a) CI, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₄ lower alkyl (in particular CH₃), (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁶) wherein R⁶ and R⁸ are the same or different and each represents H or lower C₁₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated lower C₁₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

CI, Br, F, OMe, NO, and CF₃, and (I) -OCOR¹¹, wherein R¹¹ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group or a phenyl group.

- 3. A compound according to any preceding claim wherein the Ar group is a substituted or unsubstituted (preferably aromatic), heterocyclic group, said heterocyclic group containing from 5 to 10 ring atoms, wherein at least one of the ring atoms is a nitrogen atom and any substituent on the ring is as defined as for Claim 1.
- 4. A compound according to any preceding claim wherein Ar represents pyridyl or indolyl.
 - 5. A compound according to Claim 1 wherein Ar represents a substituted or unsubstituted (preferably aromatic), carbocyclic group, said carbocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein

the or each ring contains 5 or 6 ring atoms, and any substituents on the Ar group being independently selected from the group consisting of:

(a) CI, (b) Br, (c) $\not\in$, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₄ lower alkyl (in particular CH₃), (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or lower C₁₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated lower C₁₈ straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

CI, Br, F, OMe, NO₂ and CF₃,

- and (I) -OCOR¹¹, wherein R¹¹ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group or a phenyl group.
- 6. A compound according to any preceding claim wherein any substituents on the Ar group are selected from the group consisting of: NHCOCH₃, N(R⁶)(R⁶), OR¹⁰ and -OCOR¹¹, wherein R⁶, R⁸, R¹⁰ and R¹¹ are as defined in Claim 1.
- 7. A compound according to any preceding claim wherein Ar is substituted with on or more OR^{10} groups, wherein R represents a saturated or unsaturated lower C_{1-8} straight or branched hydrocarbyl group.
- 8. A compound according to Claim 7 wherein R¹⁰ represents methyl.
- 9. A compound according to any of Claims 5 to 8 wherein Ar is selected from phenyl or phenyl substituted with 1, 2 or 3 methoxy groups.
- 10. A compound according to any preceding claim wherein R represents an unsaturated lower C₁₋₆ straight or branched hydrocarbyl group.
- 11. A compound according to Claim 10 wherein R represents OCH=C(CH₃)₂, OCH₂CMe=CH₂, OCH₂CH=CH₂ or OCH₂C=CH.

20

25

- 12. A compound according to Claim 1 wh rein Ar is selected from phenyl, trimethoxyphenyl, 3-pyridyl, 4-pyridyl or 3-indolyl; and R is selected from OCH=C(CH₃)₂, OCH₂CMe=CH₂, OCH₂CH=CH₂ or OCH₂C≡CH.
- 5 13. A compound according to any preceding claim wherein R¹ represents a lower C₁₋₆ straight or branched hydrocarbyl group.
 - 14. A compound according to Claim 13 wherein R¹ represents methyl.
 - 15. A compound according to Claim 5 wherein:

Ar represents

phenyl, which may be unsubstituted or substituted by one, two or three substituents independently selected from

CI, Br, F, OMe, NO₂, CR₃, C₁₋₄ lower alkyl (in particular CH₃), NMe₂, NEt₂, SCH₃ and NHCOCH₃;

thienyl, 2-furyl, 3-pyridyl, 4-pyridyl or indolyl.

R represents

OH or OCH₂R¹, wherein R¹ is selected from -CH=CMe₂, -CMe=CH₂, -CH=CH₂ and -C=CH.

- 16. A compound according to any preceding claim wherein R⁶ and R⁸ are the same or different and each represents H or lower C₁₋₄ alkyl.
- 17. A compound according to any preceding claim wherein R¹⁰ and R¹¹ represents a saturated or unsaturated C₁₋₈ straight chain or branched hydrocarbyl group.
- 18. A compound according to any Claim 17 wherein R¹⁰ and R¹¹ are selected from methyl, ethyl, n-propyl or isopropyl.

20

5 .

- A compound of Formula (I) selected from the following: 19.
- 1-[4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one (VIB 106),
- 1-[4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 119),
- 1-[4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxyphenyl)propen-1-one (VIB 120),
- 1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one VIB 122),
- 1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 121).
- 1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(3-methoxyphenyl)propen-1-one (VIB 162),
- 1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxyphenyl)propen-1one (VIB 123),
- 1-[4-methyl-7-(allyloxy)coumatin-8-yl]-3-phenylpropen-1-one (VIB 158),
- 1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-(pyridin-3-yl)propen-1-one (VIB 161),
- 1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-(3-methoxyphenyl)propen-1-one (VIB 159),
- 1-[4-methyl-7-(allyloxy) oumarin-3-yl]-3-(3,4,5-trimethoxyphenyl)propen-1-one (VIB 160),
- 1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxyphenyl)propen-1-20 one (VIB. 126),
 - 1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 124),
 - 1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(pyridin-3-yl)propen-1-one (VIB 125),
 - 1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(3-methoxyphenyl)propen-1-one (VIB 163).
 - A compound of Formula (I) as defined in any preceding claim for use as a 20. antiproliferative medicament.

ÖN

5

10

15

- 21. Use of a compound of Formula (I) as defined in any preceding claim for the manufacture of a medicament for the treatment or prevention of neoplasms.
- 22. Use according to Claim 21 wherein the neoplasms are located in the uterus, ovary or breast.
- 23. Use according to Claim 21 or 22 of a compound of Formula (I) for the manufacture of a medicament for the treatment of paclitaxel- and docetaxel-resistant cancer cells.
- 24. Use according to any of Claims 21 to 23 of a compound of Formula (I) in the manufacture of an antiproliferative medicament for combination therapy.
- 25. Use according to Claim 24 of a compound of Formula (I) in the manufacture of an antiproliferative medicament in combination with one or more antineoplastic agents.
- 26. The use according to Claim 25 wherein the antineoplastic agent comprises paclitaxel or docetaxel.
- 27. The use according to Claim 19 in the manufacture of a medicament for the treatment or prevention of menopausal disorders and osteoporosis.
 - 28. A pharmaceutical composition comprising one of more of the compounds of Formula (I) as defined in any preceding claim, in combination with one or more pharmaceutically acceptable excipients.
 - 29. A pharmaceutical composition according to Claim 28 further comprising one or more antineoplastic agents.

30. A pharmaceutical composition according to Claim 29 wherein the antineoplastic agent is selected from paclitaxel or docetaxel.

MANO